|
Effectiveness of BufferGel as a Vaginal Contraceptive Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on Effectiveness of BufferGel as a Vaginal Contraceptive conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Effectiveness of BufferGel as a Vaginal Contraceptive Clinical research trials and Effectiveness of BufferGel as a Vaginal Contraceptive medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including Effectiveness of BufferGel as a Vaginal Contraceptive. Effectiveness of BufferGel as a Vaginal Contraceptive Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Effectiveness of BufferGel as a Vaginal Contraceptive clinical trial. Participants oftentimes recieve the finest healthcare available for their Effectiveness of BufferGel as a Vaginal Contraceptive condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Effectiveness of BufferGel as a Vaginal Contraceptive  Effectiveness of BufferGel as a Vaginal Contraceptive
Effectiveness of BufferGel as a Vaginal Contraceptive
For Condition: Pregnancy
Status: Recruiting
Sponsor(s): National Institute of Child Health and Human Development (NICHD) ,
Synopsis: BufferGel is a new contraceptive gel designed to be used with a diaphragm. In addition to preventing pregnancy, BufferGel may also prevent some types of sexually transmitted diseases (STDs). This study will compare BufferGel to Gynol II, a currently available contraceptive gel.
Details: Vaginal acidity is thought to be one means by which the vagina prevents overgrowth or colonization by harmful microbial flora. Sperm and many STD pathogens, including HSV-1 and HSV-2, Neisseria gonorrhoeae, Treponema pallidum, Haemophilus ducreyi, and a variety of bacterial vaginosis-associated bacteria, are inactivated at pH less than 5 in vitro. BufferGel, a vaginal spermicide and microbicide, is an acidic buffer that maintains the vagina at or near its natural state of mild acidity. Formulated at vaginal pH (pH 3.9), BufferGel prevents or limits the semen-induced rise in vaginal pH. Carbopol 974P, the buffering agent in BufferGel, is a high molecular weight, cross-linked, polyacrylic acid used as a gelling or tableting agent in many pharmaceuticals; it has a well-documented record of mucosal safety in animals and humans. This study will determine the safety and contraceptive efficacy of BufferGel spermicide used with a diaphragm compared to Gynol II spermicide used with a diaphragm. The study will also measure the frequency of bacterial vaginosis, urinary tract infections, and cervical lesions in women using BufferGel compared with Gynol II. Participants in this study will be fitted for a diaphragm and randomized to receive either BufferGel or Gynol II. All participants will be instructed on the use of the test product with the diaphragm. Participants will be followed through 6 menstrual cycles (approximately 7 months) and will have 4 study visits and one study phone call. Some participants may enroll in an extended version of the study and be followed for an additional 6 cycles and 2 additional study visits. Study visits will include a gynecologic exam, Pap smear, and blood and urine tests. Participants will be asked to keep a diary to record information on product use. Some participants may also be asked to enroll in a colposcopy substudy. These participants will undergo colposcopy at study entry and after cycles 1, 3 and 6.
Eligibility:
Study Type: Interventional, Prevention, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/45 Years
Genders: Female
Protocol Entry Criteria: Inclusion Criteria - General good health - Sexually active, at risk for pregnancy, and desiring contraception - Low-risk for HIV or STD infection - Single sexual partner who is at low-risk for HIV or STD infection for 6 months prior to study entry - Expect to have same sexual partner for duration of the study - Normal cyclic menses with a usual length of 21 to 35 days - Documented history of at least two spontaneous, normal menstrual cycles since delivery, abortion, or after discontinuing hormonal contraception/hormonal therapy - Willing to accept a risk of pregnancy - Willing to engage in an average of 1 to 2 acts of heterosexual vaginal intercourse per week for a period of 6 months - Willing to be fitted with a diaphragm and use the diaphragm with test product during all acts of heterosexual vaginal intercourse for the duration of the study - Willing to only use the test product with diaphragm as the sole method of contraception over the course of the study (with the exception of emergency contraceptive pills when indicated) - Capable of using the product and diaphragm properly - Willing to keep a diary to record coital information, product use information, information about the use of other vaginal products, and sign and symptom data for self and partner - Agree not to participate in any other clinical trials during the course of the study - Written informed consent to participate in the trial Participant's Sexual Partner Must Not Be/Have - Infertile - Treated for Chlamydia trachomatis or Neisseria gonorrhoeae in the 6 months prior to study entry - HIV infected - More than one sexual partner in the 4 months prior to study entry - Engaged in homosexual intercourse - Shared injection drug needles in the 6 months prior to study entry - Allergy or sensitivity to spermicides or products containing Nonoxynol 9 or latex Exclusion Criteria - Pregnant or desire to become pregnant during the course of the study - History of infertility or conditions that may lead to infertility - Allergy or sensitivity to spermicides or products containing Nonoxynol 9 or latex - History of toxic shock syndrome (TSS) - Two or more urinary tract infections (UTIs) in the 12 months prior to study entry - Current suspected or diagnosed urinary tract infection or vaginitis - Contraindications to pregnancy (medical condition or chronic use of medications contraindicated for pregnancy) - Treated with antibiotics for pelvic inflammatory disease (PID) without a subsequent intrauterine pregnancy - More than one sexual partner in the 4 months prior to study entry - Shared injection drug needles in the 6 months prior to study entry - HIV infected or suspected HIV infection - Genital herpes simplex virus (HSV) infection with the first occurrence (initial episode) within 3 months prior to study entry or have clinical evidence of HSV on exam - Sexually transmitted diseases (STDs) in the 3 months prior to study entry - Lactating or breastfeeding - Abnormal vaginal bleeding or spotting in the month prior to study entry - Lower abdominal or pelvic pain in the month prior to study entry - Abnormal finding on pelvic examination which, in the view of the study investigator, precludes participation in study - Vaginal or cervical irritation, including vaginal or cervical epithelial disruption, ulceration, bleeding, petechiae, sloughing, or areas of obvious erythema - Vaginal or cervical biopsy or surgery in the 3 months prior to study entry - Vaginal or systemic antibiotics, antivirals, or antifungals in the 14 days prior to study entry - Depo-Provera injection in the 10 months prior to study - Vaginal or cervical abnormality that would interfere with the proper placement and retention of test product and diaphragm - Abnormal Pap smear in the 12 months prior to study entry - Consume (on average) greater than 2 to 3 alcoholic beverages per day - Drug abuse (recreational, prescription, or OTC) in the 12 months prior to study entry - Investigational drug or device use in the month prior to study entry - Previously participated in or completed this study
Total Enrollment: 975
Location and Contact Information:
Overall Study Official:
H.MacKay, Study Director, National Institute of Child Health and Human Development (NICHD)
University of Pennsylvania *Recruiting*
Philadelphia, Pennsylvania,
United States
Recruiting Lorie Maloney 215-662-2935
New York University *Recruiting*
New York City, New York,
United States
Recruiting Anna Davis 212-263-6253
Eastern Virginia Medical School *Recruiting*
Norfolk, Virginia,
United States
Recruiting Joann Cooper 757-446-7254
Columbia University *Recruiting*
New York City, New York,
United States
Recruiting Nancy Gallagher 212-305-0947
California Family Health Council *Recruiting*
Berkeley, California,
United States
Recruiting Amber Kessel 510-647-0632
University of Cincinnati *Recruiting*
Cincinnati, Ohio,
United States
Recruiting Debbie Boerschig 513-584-5361
University of Pittsburgh *Recruiting*
Pittsburgh, Pennsylvania,
United States
Recruiting Lynn Reid 412-641-5496
University of Colorado *Recruiting*
Denver, Colorado,
United States
Recruiting Heather Hughes 720-848-1687
California Family Health Council *Recruiting*
Los Angeles, California,
United States
Recruiting Karen Peacock 213-386-5614
Additional Information:
Study ID Numbers: NICHD-RFP-2000-16;
Study Start Date: September 2001
Record last reviewed: June 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00065858
Other Pregnancy Studies:
1. A Study to Evaluate the Safety and Tolerance of Combination Anti-HIV Drug Therapy (Indinavir, Lamivudine, and Zidovudine) in HIV-Positive Pregnant Women and Their Infants
2. Vulnerability of the Fetus/Infant to PAH, PM2.5 AND ETS.
3. A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT)
4. Treatment of Infertility in Women With Polycystic Ovary Syndrome
5. Effectiveness of BufferGel as a Vaginal Contraceptive
Related Studies:
Other Pregnancy Clinical Trials
Other Pennsylvania Clinical Trials
Other Philadelphia Clinical Trials
Effectiveness of BufferGel as a Vaginal Contraceptive
|
|
|
|
|
|
|
|
